Aurora Cannabis Q4 Earnings Expected Wednesday Amid Cost-Cut Push

Consensus Estimates Point to Narrower Loss

Wall Street expects Aurora to report a net loss of C$12.8 million for the quarter ended March 31, down from a C$22.1 million loss in the prior quarter. Revenue is forecast at C$68.4 million, flat sequentially but down 11 percent year-over-year, according to consensus estimates compiled by FactSet. The company generated C$68.3 million in revenue in the December quarter.

Aurora has guided to positive adjusted EBITDA for the full fiscal year, a target it reiterated in February after posting a C$4.2 million adjusted EBITDA profit in Q3. Hitting that mark would require the company to maintain profitability in the March quarter despite seasonal headwinds in the Canadian recreational market.

Medical Cannabis Revenue Remains Key Variable

Aurora's international medical business accounted for 38 percent of total revenue in Q3, and any variance from the C$26 million quarterly run rate will move the headline number. The company ships bulk flower and finished products to Germany, Australia, and the United Kingdom under supply agreements with national health systems. Germany's recreational legalization in April 2025 shifted some patient volume out of the medical channel, pressuring Aurora's highest-margin segment.

Canadian recreational revenue has declined for three straight quarters, dropping to C$42.1 million in Q3 from C$48.7 million a year earlier. Aurora exited the value segment in late 2025, ceding share to discount brands in favor of premium SKUs with better gross margins. That strategic pivot is still playing out.

Cost Cuts and Restructuring Timeline in Focus

Aurora announced a C$30 million annualized cost-reduction program in November 2025, targeting SG&A and production overhead. The company closed its Polaris facility in December and consolidated cultivation at its flagship Aurora Sky and Edmonton operations. Management said the full savings would be visible by the June 2026 quarter. Wednesday's results should show partial progress.

Operating expenses hit C$41.2 million in Q3, down from C$48.9 million a year earlier but still elevated relative to the current revenue base. Investors will scrutinize the SG&A line for evidence that the restructuring is on track. For full context on Aurora's restructuring efforts, see the CannIntel topic hub on Aurora Cannabis earnings.

What to Watch on the Call

Three variables will determine how the market reads the quarter: adjusted EBITDA margin, cash burn, and forward guidance for fiscal 2027. Aurora ended December with C$147 million in cash and no drawn debt, giving it runway through mid-2027 at current burn rates. Any update to the cash-flow forecast or discussion of additional cost actions will be closely parsed.

Consensus estimates model C$275 million in revenue for fiscal 2027, implying flat to slightly positive growth from fiscal 2026, though the company hasn't issued formal guidance yet. Management commentary on the German market and Canadian premium-tier share trends will shape that outlook. The earnings call is scheduled for 8:30 a.m. Eastern on June 11.